NEW YORK/WASHINGTON (Reuters) – U.S. insurance regulators and state attorneys general are lining up to scrutinize Aetna Inc’s proposed $33 billion takeover of rival Humana Inc for potential harm to consumers, complicating what is already expected to be a tough and lengthy review by federal antitrust authorities.